CDKN1B and breast carcinoma: Treatment of Her2+ breast cancer cells with the Her2−specific antibody trastuzumab or the dual-Her2/EGFR inhibitor Lapatinib results in cell cycle arrest, possibly due to increased p27 protein levels [29].